Drug intelligence / Profile preview

PM54

Development stage: Phase 2
Lead developer: PharmaMar
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Intravenous

Overview

PM54 is a novel synthetic derivative of lurbinectedin, developed by PharmaMar as an experimental anticancer agent. It functions as a next-generation transcriptional inhibitor, exhibiting potent antitumor activity in preclinical models, particularly against melanoma and soft tissue sarcoma. The compound acts by suppressing super-enhancer-driven oncogenic transcription, leading to S-phase cell cycle arrest and DNA damage in cancer cells. PM54 is currently being evaluated in phase I clinical trials for advanced solid tumors, with administration via intravenous infusion every 21 days[1][2][3][4][5][7].

Targets

26S proteasomePol II (RNA polymerase II elongation factors)

Beyond the preview

Go deeper on PM54.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PM54.

Explore the full profile